questionText: To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the reasons for the difference in availability of Omaveloxolone (Skyclarys) as a treatment for Friedrich's ataxia in (a) Scotland and (b) England and Wales; and if he will make it his policy to require the National Institute for Health and Care Excellence to set out the reasons for which new drugs that (i) have been approved by the Medicines and Healthcare products Regulatory Agency and (ii) are available in Scotland are not available in England and Wales.
answerText: The Department has made no assessment of the reasons for the difference in the availability of omaveloxolone (Skyclarys) as a treatment for Friedrich's ataxia in Scotland, England, and Wales.Decisions on the availability of medicines are taken by the resp...
heading: Omaveloxolone